Europe’s reaction to CAVOMP’s harmonization in the orphan drugs space

There are conflicting opinions about CAVOMP and how far it will go with harmonizing reimbursement policies among the 27 countries in the EU. We need to remember that sovereignty issues to consider as well. Governments, the EMA, industry, payers and patients, all feel that more collaboration is necessary in order to align everyone's interests. It may also be necessary to …